PROGRAM OF STUDIES ON THE BIOLOGY AND TREATMENT OF HUMAN

人类生物学和治疗研究计划

• 批准号: 3093534
• 负责人: STUART F SCHLOSSMAN
• 金额: $ 221.61万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-08-01 至 1994-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3093534
• 关键词: acute lymphocytic leukemia; acute myelogenous leukemia; antileukemic agent; human subject; lymphoma; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; pediatric neoplasm /cancer

The present proposal takes advantage of the wealth of clinical and basic investigative resources at the Dana-Farber Cancer Institute and its collaborative hospitals to develop an integrated program in both basic and clinical research. The principal goals of this program Project Grant are directed at the regulation of both leukemic and normal hematopoietic cell growth and differentiation and the development of novel immunotherapy, chemotherapy and transplantation treatment programs for adult and childhood leukemia and lymphoma. The basic studies include the following six proposals: A3) studies on the Regulation of Proliferation and Differentiation of Human Acute Myeloblastic Leukemic Cells (Griffin). A5) C-FmS and CSF-1 Gene Expression in Myeloid Differentiation and Leukemia (Kufe); A8) CD20, A B Lymphocyte-Specific Ion Channel That Regulates Proliferation and differentiation (Tedder); A9) Detection of Minimal Residual Lymphoid neoplasia by N-PCR (Sklar); A10) Regulation of the Gene for the Human Stem Cell Antigen CD34 in Normal and Leukemic Cells (Tenen); All) Novel Lymunotherapeutic Strategies (Schlossman and Breitmeyer). There are three major clinical research projects and they include; B2) Childhood Acute Lymphoblastic Leukemia (Sallan); B5) Multi-Disciplinary Strategies for the Treatment of Acute Myeloid Leukemia (Ritz); and B6) B Cell Non-Hodgkins Lymphoma; New Therapeutic Strategies (Nadler).

目前的建议利用了丰富的临床和基础 丹娜-法伯癌症研究所的调查资源及其 合作医院制定一个综合方案，在基本和 临床研究 该计划项目赠款的主要目标是针对 调节白血病和正常造血细胞生长， 分化和发展新的免疫疗法，化疗和 成人和儿童白血病的移植治疗计划， 淋巴瘤 基础研究包括以下六项建议： 人乳腺癌细胞增殖分化调控的研究 急性成髓细胞白血病细胞（格里芬）。 A5）C-FmS和CSF-1基因 在髓系分化和白血病（Kufe）中的表达; A8）CD 20，A B 淋巴细胞特异性离子通道调节增殖和 分化（Tedder）; A9）检测最小残留的类磷脂 通过N-PCR（Sklar）的瘤形成; A10）人类干细胞基因的调节 正常和白血病细胞中的细胞抗原CD 34（Tenen）;所有）新 Lymuntal Strategies（Schlossman and Breitmeyer）. 有三 主要临床研究项目，包括：B2）儿童急性 淋巴母细胞白血病（Sallan）; B5）多学科策略 急性髓性白血病的治疗（Ritz）;和B6）B细胞非霍奇金淋巴瘤 淋巴瘤;新的治疗策略（Nadler）。